Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

13.31 +0.66 (+5.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about RAPT Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
10 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q2 2024
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics: Q4 Earnings Insights
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Schall Law
Via GlobeNewswire
What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?
RAPT Therapeutics closes Phase 2 trials for zelnecirnon in atopic dermatitis & asthma following FDA clinical hold due to liver failure. 
Via Benzinga
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
 
Via Benzinga
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q1 2024
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
RAPT Therapeutics Reports First Quarter 2024 Financial Results
Company maintains solid cash position of $141.6 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
From RAPT Therapeutics, Inc.
Via GlobeNewswire
3 Biotech Stocks to Dump Before They Go to Zero
These biotech stocks to sell are burning through cash at an alarming rate and seem destined for zero, making them prime targets for selling. 
Via InvestorPlace
RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Company maintains solid cash position of $158.9 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Rivian Automotive Reports Q4 Loss, Joins Etsy, Lucid Group And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures trading higher by around 2% on Thursday. 
Via Benzinga
What's Going On With RAPT Therapeutics Stock On Wednesday?
Latest developments in RAPT Therapeutics as FDA places clinical hold on Phase 2b trial for zelnecirnon in dermatitis and asthma. Stock rebounds and analyst downgrades. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of International Flavors & Fragrances Inc. (NYSE: IFF) fell during Wednesday’s session after the company reported mixed fourth-quarter financial results and reduced its expected quarterly... 
Via Benzinga
Stocks Slip Ahead Of Fed Minutes, Nvidia Earnings
Stocks are lower today, with the Nasdaq Composite Index (IXIC) leading the losses as investors reassess a potentially overvalued tech sector. 
Via Talk Markets
Topics Economy Stocks
Crude Oil Moves Lower; Summit Therapeutics Shares Plummet
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 200 points on Tuesday. The Dow traded down 0.18% to 38,557.86 while the NASDAQ fell 1.30% to 15,570.84. The... 
Via Benzinga
Topics Stocks
Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Why Is Inflammatory Disease/Oncology-Focused RAPT Therapeutics Shares Tumbling Today?
FDA places clinical hold on RAPT Therapeutics' Phase 2 trials for zelnecirnon in atopic dermatitis and asthma. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.